Active, Not Recruiting
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
NCT05661955
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +26 more
- Locations
-
- Beijing Cancer Hospital Beijing, Beijing Municipality, China
- Fujian Cancer Hospital Fuzhou, Fujian, China
- The Second Hospital and Clinical Medical School, Lanzhou University Lanzhou, Gansu, China
- Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong, China